End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.64 USD | -7.57% | -15.17% | -14.39% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 124.1 | 148.1 | - | - |
Enterprise Value (EV) 1 | 124.1 | 3.962 | 4.977 | 57.21 |
P/E ratio | -2.04 x | -2.57 x | -1.2 x | -0.87 x |
Yield | - | - | - | - |
Capitalization / Revenue | 62 x | - | - | - |
EV / Revenue | 62 x | - | - | - |
EV / EBITDA | - | - | - | - |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 22,896 | 31,914 | - | - |
Reference price 2 | 5.420 | 4.640 | 4.640 | 4.640 |
Announcement Date | 3/25/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | 2 | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -30.74 | -59.25 | -143.5 | -209.5 |
Operating Margin | - | -1,537% | - | - | - |
Earnings before Tax (EBT) 1 | - | -27.88 | -61.05 | -119.1 | -186.7 |
Net income 1 | -30.5 | -27.88 | -60.6 | -119.3 | -185.9 |
Net margin | - | -1,393.8% | - | - | - |
EPS 2 | -165.3 | -2.660 | -1.806 | -3.872 | -5.332 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 2 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -7.057 | -7.452 | -9.466 | -8.768 | -10.97 | -14.45 | -21.8 | -27.19 | -29.38 |
Operating Margin | - | -372.6% | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.785 | -6.353 | -8.151 | -6.629 | -11.49 | -16.52 | -26.42 | -27.19 | -29.38 |
Net income 1 | -6.785 | -6.353 | -8.151 | -6.629 | -11.43 | -16.68 | -25.88 | -27.19 | -29.38 |
Net margin | - | -317.65% | - | - | - | - | - | - | - |
EPS 2 | -35.80 | -0.3500 | - | -0.2300 | -0.3580 | -0.4800 | -0.7060 | -0.9300 | -1.000 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/21/23 | 11/13/23 | 3/25/24 | 5/15/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | - | 144 | 143 | 90.9 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.39% | 148M | |
+55.70% | 59.34B | |
+43.00% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+2.72% | 12.49B | |
+25.85% | 12.28B |
- Stock Market
- Equities
- SGMT Stock
- Financials Sagimet Biosciences Inc.